UK allows pre-implantation tissue typing
This article was originally published in Clinica
The Human Fertilisation and Embryology Authority (HFEA) has decided, "in principle", to allow tissue typing to be used in conjunction with preimplantation genetic diagnosis (PGD) for "severe genetic disease". The decision enables the selection of embryos that are not only free from a specific congenital disease but in which the blood from its umbilical cord might be used in the treatment of a sibling affected by the disease.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.